Public Employees Retirement System of Ohio Trims Position in Insulet Corporation $PODD

Key Points

• The Public Employees Retirement System of Ohio reduced its stake in Insulet Corporation by 4.4%, holding approximately $12.87 million worth of shares after selling 1,895 shares.
• Insulet reported better-than-expected earnings with $1.17 EPS for the last quarter, surpassing analyst estimates of $0.92, and demonstrated a 32.9% year-over-year revenue increase.
• Several institutional investors notably increased their holdings in Insulet, with Vanguard Group acquiring an additional 178,976 shares in the last quarter, showing continued confidence in the company's performance.

Public Employees Retirement System of Ohio trimmed its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 4.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,956 shares of the medical instruments supplier's stock after selling 1,895 shares during the quarter. Public Employees Retirement System of Ohio owned approximately 0.06% of Insulet worth $12,868,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after purchasing an additional 178,976 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after purchasing an additional 297,734 shares in the last quarter. Groupama Asset Managment increased its holdings in shares of Insulet by 0.4% during the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock valued at $276,728,000 after purchasing an additional 3,759 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Insulet by 4.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock valued at $177,096,000 after purchasing an additional 27,408 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Insulet by 27,298.6% during the 1st quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock valued at $1,744,100,000 after purchasing an additional 661,717 shares in the last quarter.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Price Performance

Shares of NASDAQ PODD opened at $318.00 on Friday. The firm has a market cap of $22.38 billion, a PE ratio of 96.66, a PEG ratio of 2.69 and a beta of 1.36. The firm has a fifty day moving average of $319.01 and a 200 day moving average of $296.63. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a one year low of $225.37 and a one year high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same quarter in the previous year, the company posted $0.55 EPS. The firm's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PODD. Royal Bank Of Canada lifted their target price on shares of Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insulet in a report on Thursday, August 7th. The Goldman Sachs Group initiated coverage on shares of Insulet in a report on Friday, May 30th. They issued a "buy" rating and a $380.00 price target for the company. Piper Sandler boosted their price target on shares of Insulet from $320.00 to $360.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Finally, Wells Fargo & Company boosted their price target on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a report on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $343.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.